Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Aldesleukin Pregnancy and Breastfeeding Warnings

Aldesleukin is also known as: Proleukin

Medically reviewed on Aug 6, 2018

Aldesleukin Pregnancy Warnings

Use is recommended only if the potential benefit justifies the possible fetal risk.

US FDA pregnancy category: C

-Sexually active women and men should use effective contraception during treatment.
-This drug should not be administered to fertile persons of either gender who are not practicing effective contraception.

Animal studies have revealed evidence of embryolethality at doses 27 to 36 times the human dose, and significant maternal toxicities at doses 2.1 to 36 times the human dose. No teratogenicity has been observed other than that attributed to maternal toxicity.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Aldesleukin Breastfeeding Warnings

Breastfeeding is not recommended during treatment.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.

References for breastfeeding information

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.